Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Eisai Europe Ltd

Prof. Josep Llovet and Prof. Stephen L. Chan discuss which patients can benefit, and they provide guidance on implementation of dosing strategies and patient pre-habilitation, for prediction of efficacy and toxicity.

 

In this podcast, Prof. Josep Llovet and Prof. Stephen L. Chan describe patients who can benefit from monotherapy, and they  share current guidance on implementation of dosing strategies for the management of toxicity in clinical practice. They discuss first line monotherapy with TKI (lenvatinib or sorafenib) for patients who are not suitable for the treatment with atezo-bev combination (around 20% of the patients), which is the current standard of care. They summarize the HCC patients who are not ideal for this I/O combination, such as HCC patients with liver transplantation, high bleeding risk, impaired liver function or severe autoimmune disease.

 

The experts discuss which patients can benefit from TKI and provide a summary of efficacy and safety data from several pivotal clinical studies (including SHARP, REFLECT, IMbrave150), as well as real-world data. Dosing strategies for VEGFR-TKIs and management of AEs are discussed, as well as guideline recommendations. Finally, the experts anticipate key developments over the next few years, focusing on the new immunotherapy combinations that could become new standard of care.

 

This HCC CONNECT podcast is also available on
Castos, Spotify, Apple Podcasts, and Google Podcasts.

Prof. Josep Llovet has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Bristol-Myers Squibb, Boehringer-Inelheim, Eisai Inc, Eli Lilly and Ipsen. 

Prof. Stephen L. Chan has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astra-Zeneca, MSD, Eisai and BMS 

Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Eisai Europe Ltd

Prof. Josep Llovet and Prof. Stephen L. Chan discuss which patients can benefit, and they provide guidance on implementation of dosing strategies and patient pre-habilitation, for prediction of efficacy and toxicity.

 

In this podcast, Prof. Josep Llovet and Prof. Stephen L. Chan describe patients who can benefit from monotherapy, and they  share current guidance on implementation of dosing strategies for the management of toxicity in clinical practice. They discuss first line monotherapy with TKI (lenvatinib or sorafenib) for patients who are not suitable for the treatment with atezo-bev combination (around 20% of the patients), which is the current standard of care. They summarize the HCC patients who are not ideal for this I/O combination, such as HCC patients with liver transplantation, high bleeding risk, impaired liver function or severe autoimmune disease.

 

The experts discuss which patients can benefit from TKI and provide a summary of efficacy and safety data from several pivotal clinical studies (including SHARP, REFLECT, IMbrave150), as well as real-world data. Dosing strategies for VEGFR-TKIs and management of AEs are discussed, as well as guideline recommendations. Finally, the experts anticipate key developments over the next few years, focusing on the new immunotherapy combinations that could become new standard of care.

 

This HCC CONNECT podcast is also available on
Castos, Spotify, Apple Podcasts, and Google Podcasts.

Prof. Josep Llovet has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Bristol-Myers Squibb, Boehringer-Inelheim, Eisai Inc, Eli Lilly and Ipsen. 

Prof. Stephen L. Chan has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astra-Zeneca, MSD, Eisai and BMS 

Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Eisai Europe Ltd
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Eisai Europe Ltd
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Eisai Europe Ltd
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Eisai Europe Ltd
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

micro-learning Micro learning - Video, slides and more

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning - Video, slides and more

Module

3

of 4

module
Oncology 
The expanding role of immunotherapy in HCC

Module 3: Combining locoregional and systemic treatments in intermediate HCC

Experts
Prof. Aiwu Ruth He, Prof. Beau Toskich
Endorsed by
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Apr 2025
  • Non-accredited Independent Medical Education

AstraZeneca has provided a sponsorship grant towards this independent programme.
podcast Video podcast

Episode

4

of 4

episode
Oncology 
HCC podcast series part 4: Intermediate HCC – the evolving role of IO

Integrating multimodal approaches with multidisciplinary care

Experts
Dr Edward Kim, Dr Nina Sanford, Dr Mark Yarchoan, Oncology Brothers (Moderators)
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jan 2025
  • Non-accredited Independent Medical Education

AstraZeneca has provided a sponsorship grant towards this independent programme.
podcast Video podcast

Episode

3

of 4

episode
Oncology 
HCC podcast series part 3: Intermediate HCC – treatment options and strategies

Expert insights on systemic, loco-regional, and multimodal therapies

Experts
Dr Maria Reig, Dr Emil I Cohen, Oncology Brothers (Moderators)
Endorsed by
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast

Episode

2

of 4

episode
Oncology 
HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch

Medical experts discuss how to approach sequencing in clinical practice

Experts
Prof. Arndt Vogel, Assoc. Prof. Lorenza Rimassa, Oncology Brothers (Moderators)
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Dec 2024
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update

Episode

4

of 4

episode
Oncology 
Highlights from ESMO 2026

Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers

Experts
Dr Elizabeth Smyth, Dr Yelena Janjigian, Assoc. Prof. Gerald Prager, Prof. Hong Jae Chon, Assoc. Prof. Lorenza Rimassa, Dr Tom Newsom-Davis, Dr Louise Lim, Dr Komal Jhaveri, Dr Roberto Iacovelli
Endorsed by
  • download Downloadable
    Resources
  • clock 9 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education